Outpatient & Home Infusion Referral Market Paper
Medicare infusion administration and infused biologics · states · rheumatology, GI, neurology and ID/OPAT pathways
The Medicare infusion market by drug, administration code and state, plus four referral-source pathways sized from the biologics and IV therapies prescribing specialists bill. ID/OPAT Medicare dollars understate that market because most home IV antibiotics are billed outside Part B.
Built for Ambulatory infusion center operators, home infusion liaisons, specialty pharmacy teams and infusion investors.
What's inside the full paper
- Executive summary
- Infusion codes nationally
- State ranking
- Referral pathway: Rheumatology infusion referral sources (RA, lupus, spondyloarthritis)
- Referral pathway: GI infusion referral sources (Crohn's and ulcerative colitis)
- Referral pathway: Neurology infusion referral sources (MS, myasthenia, CIDP)
- Referral pathway: Infectious disease / OPAT referral sources (IV antibiotics)
- How to use this with RepVector
- Methods and limits
Free preview
Executive summary
Prepared 2026-11-22 from the CMS Medicare Physician & Other Practitioners by Geography and Service file (latest release), read live. Across 15 infusion administration and infused-drug codes, Original Medicare paid an estimated $2,453,266,763.
The largest states are Florida ($277,392,773), Texas ($210,816,640), California ($181,793,787), New York ($117,054,131), North Carolina ($112,785,330). The top five hold 36.7% of the national total.
This paper also sizes 4 referral-source pathways (rheumatologists; gastroenterologists; neurologists; infectious disease physicians and hospitalists) by the procedures and drugs those clinicians bill. These identify prospects to call on, not confirmed referrers or referral volume.
Infusion codes nationally
Providers and beneficiaries are the larger of the office/facility rows per code, not a sum. Payment = CMS average Medicare payment × services.
| Code | Description | Providers | Beneficiaries | Services | Medicare payment |
|---|---|---|---|---|---|
| J0129 | Injection, abatacept, 10 mg (code may be used for medicare when drug a | 4,252 | 25,596 | 16,527,204 | $554,799,816 |
| J3380 | Injection, vedolizumab, intravenous, 1 mg | 5,592 | 11,319 | 19,489,392 | $334,780,924 |
| J3262 | Injection, tocilizumab, 1 mg | 3,709 | 14,162 | 56,601,164 | $263,325,890 |
12 more rows in the full paper
State ranking
Rendering-provider state. Billing providers is the largest single-code count (providers bill several codes, so they are not summed).
| State | Billing providers | Services | Medicare payment | Share |
|---|---|---|---|---|
| Florida | 1,926 | 13,555,245 | $277,392,773 | 11.3% |
| Texas | 2,125 | 9,651,533 | $210,816,640 | 8.6% |
| California | 2,281 | 8,981,168 | $181,793,787 | 7.4% |
53 more rows in the full paper
Statistical results are review leads, not findings of fraud. See our sources.
